NEW YORK, NY -- (Marketwire) -- 05/15/12 -- www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index to have free access to these research reports.
Generic drug makers such as Mylan Inc. and Watson Pharmaceuticals Inc. have been benefitting from increased sales as of late. Major drugs from the much talked about patent cliff group are now being produced by generic players, and the effect on quarterly earnings has been rosy. While sales and profits have been up, a number of lawsuits involving several companies are ongoing, as branded drug makers and rival generic companies vie for production rights. Get your free reports on Mylan Inc. and Watson Pharmaceuticals Inc. at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.
www.shinesrooms.com is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at www.shinesrooms.com. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.
Watson Pharmaceuticals, which began producing a generic version of Lipitor in November of last year, saw its 1st quarter earnings per share increase by $0.75 year-over-year to $1.64. Its Global Generics division saw sales jump by 86%, and total revenues for the quarter were $1.52 billion, considerably higher than sales from the same period last year. Watson Pharmaceuticals Inc. report is accessible for free by registering today at http://www.shinesrooms.com/WatsonPharmaceuticalsInc150512.pdf.
Mylan also turned in a strong 1st quarter, with earnings rising by over 18% year-over-year. Mylan Inc. report is accessible for free by registering today at http://www.shinesrooms.com/MylanInc150512.pdf.
The two Drugs - Generic stocks research reports are available for free by signing up now on www.shinesrooms.com.
Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.
To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.
Michael Thomas Smith